Clinical and pharmacokinetic considerations for the use of daptomycin in patients with Staphylococcus aureus bacteraemia and severe renal impairment | Zendy

Ricardo L. Chaves | Zendy; Abhijit Chakraborty | Zendy; David P. Benziger | Zendy; Stacey Tannenbaum | Zendy

Open Access

Clinical and pharmacokinetic considerations for the use of daptomycin in patients with Staphylococcus aureus bacteraemia and severe renal impairment

Author(s) -

Ricardo L. Chaves,

Abhijit Chakraborty,

David P. Benziger,

Stacey Tannenbaum

Publication year - 2013

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkt342

Subject(s) - daptomycin , medicine , staphylococcus aureus , bacteremia , pharmacokinetics , staphylococcal infections , micrococcaceae , intensive care medicine , antibacterial agent , vancomycin , antibiotics , microbiology and biotechnology , bacteria , biology , genetics

To support daptomycin dosing recommendations in patients with Staphylococcus aureus bacteraemia (SAB) and severe renal impairment using simulations from a population pharmacokinetic model for daptomycin.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research